BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34986957)

  • 1. Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR.
    Chen S; Wang Y; Wang K; Zhang L; Zhang X
    Pharmazie; 2021 Dec; 76(12):606-610. PubMed ID: 34986957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
    Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
    Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening.
    Sun Q; Pastor L; Du J; Powell MJ; Zhang A; Bodmer W; Wu J; Zheng S; Sha MY
    PLoS One; 2021; 16(10):e0244332. PubMed ID: 34610014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy.
    Fleshner P; Braunstein GD; Ovsepyan G; Tonozzi TR; Kammesheidt A
    Cancer Med; 2018 Jan; 7(1):167-174. PubMed ID: 29125240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions.
    Tsai JH; Cheng CH; Chen CC; Lin YL; Lin LI; Chen ML; Liau JY
    Histopathology; 2016 May; 68(6):810-8. PubMed ID: 26496853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status.
    Yang S; Farraye FA; Mack C; Posnik O; O'Brien MJ
    Am J Surg Pathol; 2004 Nov; 28(11):1452-9. PubMed ID: 15489648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
    Yu H; Han L; Yuan J; Sun Y
    Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating free DNA in a screening program for early colorectal cancer detection.
    Perrone F; Lampis A; Bertan C; Verderio P; Ciniselli CM; Pizzamiglio S; Frattini M; Nucifora M; Molinari F; Gallino G; Gariboldi M; Meroni E; Leo E; Pierotti MA; Pilotti S
    Tumori; 2014; 100(2):115-21. PubMed ID: 24852853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.